Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                

MRSIA Orientation 2020 - Sample Concept Note

Download as docx, pdf, or txt
Download as docx, pdf, or txt
You are on page 1of 2

Republic of the Philippines

Department of Health
Eastern Visayas
Center for Health Development

CONCEPT NOTE

MR-OPV Supplemental Immunization Activity Orientation

I. RATIONALE

The country conducted several mass immunization campaigns in 1998, 2004, 2007, 2010
and 2014 in alignment to the National Measles Elimination Plan to eliminate measles in the
country. These supplemental measles immunization campaigns were conducted to avert
measles virus transmission and prevent deaths in the most vulnerable age groups, specifically
in under-5 year old children. For the past few years, measles outbreaks were observed in
several Regions of the country due to decreasing herd immunity and increase in the number of
susceptible under-5 year old children for measles. Mass vaccinations were lastly conducted
nationwide in 2019 due to large outbreaks of measles in most Regions of the country.

Since last June of 2019, polio outbreak due to circulating vaccine derived poliovirus (cVDPV)
occurred in several areas in the country due to the detection of poliovirus in environmental and
human samples in Metro Manila, Davao, BARMM, Region IV-A, Cebu and Region III. This
showed that the country is in a very high risk situation for polio virus re-circulation after the
country has been declared polio-free in 2000. This situation prompted a National response to
avert this poliovirus transmission through the conduct of several rounds of oral polio mass
vaccination in Mindanao and NCR with the use of both monovalent OPV type 2 (mOPV2) and
bivalent oral polio vaccines (bOPV). Starting July and September, Regions III and IV-A will
conduct a mass polio immunization campaign with the use of bivalent oral polio vaccine.

To further complete this response, all remaining Regions in Luzon and the Visayas will be
conducting the bOPV mass immunization this coming October 2020.

II. OBJECTIVE

1. To orient/re-orient all concerned health staff of the Provincial/City Health Offices and
other stakeholders on the MR-OPV Supplemental Immunization Activity.

III. EXPECTED OUTPUT

1. To develop a microplan with the LGUs and different stakeholders

IV. STAKEHOLDERS PARTICIPATION

1. Local Government Units – Supports local implementation of Immunization Program


Activities.
2. Provincial DOH Office – Program Support

V. METHODOLOGY

1. Lecture – Discussion - Workshop


2. Group - Discussion

OPERATIONAL DETAILS

Date: September 3, 2020


Venue : DOH EVCHD, Palo, Leyte
Republic of the Philippines
Department of Health
Eastern Visayas
Center for Health Development

Category of participants:
(Classification or group from which the Provincial and City NIP Coordinators
participants belong. Indicate name, designation
and area of assignment)

Total number of participants: Male : 1 Female: 9


Facilitator/Resource Person/s: Ma. Elena Joy Villarosa
Dr. Milagros Salvacion Bolito
Dr. Fidelita Dico
Dr. Carmen Garado
Mr. Lambert Solis
Support Staff: Adrian Rey Ortiz
Proposed Budget:
Write the breakdown of expenses i.e. catering 13,932.50
services, venue, logistics, etc.)
Fund Source: SAA 2019-07-0901
Other requirement/s: Attendance Sheet
Certificate of Appearance
(Participants)
LCD Projector
Laptop, Functional Audio Visual
System
Backdrop
Chairs and Tables

I. PROGRAM OF ACTIVITIES

Time Activity
09:00AM-9:30AM Arrival of Participants/ Registration
Opening Program
-Preliminaries
9:30 AM -9:45AM
-Welcome Message
-Acknowledgement of participants
9:45AM-11:00AM -Presentation of MR OPV SIA Guidelines

11:00AM-12:00AM -Open Forum


12:00NN-1:00PM LUNCHBREAK
-Microplanning Workshop
1:00PM- 4:00PM
-Presentation of Microplanning
4:00PM-4:15PM Closing of Activity

Prepared by: Noted by:

Maria Elena Joy Villarosa Milagros Salvacion C. Bolito, MD, MPH


NIP Program Manager Head, FHU

Recommending Approval: Reviewed by:

Carmen P. Garado, MD, MPH Joreena Cervantes


Division Chief Training Specialist II

Approved by:

MINERVA P. MOLON, MD, MPH, FPPA, CESO III


Director IV

You might also like